Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients
NCT ID: NCT06144788
Last Updated: 2023-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
156 participants
INTERVENTIONAL
2023-11-30
2025-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
JP-2266 Low-dose
Subjects take the investigational products once a day for 12 weeks.
SGLT2 inhibitor
SGLT 1/2 dual inhibitor
JP-2266 High-dose
Subjects take the investigational products once a day for 12 weeks.
SGLT2 inhibitor
SGLT 1/2 dual inhibitor
placebo
Subjects take the investigational products once a day for 12 weeks.
SGLT2 inhibitor
SGLT 1/2 dual inhibitor
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SGLT2 inhibitor
SGLT 1/2 dual inhibitor
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Those diagnosed with type 2 diabetes
3. A person who provides diet and exercise therapy for the management of diabetes from 8 weeks before the screening criteria and can continue diet and exercise therapy during the clinical trial
4. Screening Results of the following criteria
* 7% ≤ HbA1c ≤ 10%
* FPG ≤ 270 mg/dL
5. Patients with 20 \< BMI ≤ 45 kg/㎡
6. Those who voluntarily signed the informed consent to participate in this study
Exclusion Criteria
2. Screening when the inspection meets the following criteria
* AST or ALT more than 3 times the normal upper limit
* Total bilirubin exceeds twice the normal upper limit
* eGFR \< 60 mL/min/1.73㎡
3. A person with the following medical history or history of surgery/therapy
* Medically significant history of kidney disease: kidney vascular obstruction disease, nephrectomy, kidney transplantation, etc
* History of severe gastrointestinal surgery: total gastrectomy, total colon resection, small intestine resection, gastrointestinal anastomosis, gastrointestinal bypass, etc
* history of acute pancreatitis or pancreatic surgery
* History of undergoing bariatric surgery within 2 years before screening
* Diabetic ketoacidosis, diabetic coma or whole marriage within 1 year prior to screening
* Urinary tract infections or genital infections within 1 year prior to screening
* Alcohol or drug addiction within 1 year prior to screening
* A history of severe heart disease (heart failure, unstable angina, myocardial infarction, congestive heart failure symptoms
* A person who has a history of significant surgery that causes electrolyte imbalance within 12 weeks before screening, or who is scheduled to undergo significant surgery within 12 weeks after the end of the clinical trial
* Hypertension emergency medical history within 12 weeks prior to screening
* There is a weight change of more than 10% within 12 weeks prior to screening, and symptoms of polyuria and bipolar disorder
* A person with a history of malignancy within 5 years prior to screening However, a complete cure or properly controlled basal cell cancer, squamous cell skin cancer, or cervical intraepithelial cancer is allowed, but the history of bladder cancer cannot participate even if it has been more than 5 years
4. A person who has the following diseases or signs
* Dysuria that is not medically controlled due to tense urinary incontinence, neurotic bladder, prostate hypertrophy, or symptoms of anuria, oliguria, urinary retention
* Severe diabetic complications (proliferative diabetic retinopathy, nephropathy above stage 4 or severe diabetic neuropathy)
* Chronic diseases that require continuous use of diuretics, systemic steroids or immunosuppressants (alveolar administration, injection)
* Active liver disease, hepatitis, liver failure or cirrhosis
* Patients with pituitary or adrenal insufficiency
* Severe infections requiring the use of persistent antibiotics or immunotherapy drugs, and significant clinically trauma
* an unstable mental illness that is not medically controlled
* Severe gastrointestinal diseases: active ulcers, gastrointestinal/intestinal bleeding, active inflammatory bowel syndrome, patients with biliary obstruction, active gastritis not controlled by medication, etc
5. A person who has a history of hypersensitivity to the ingredients of a clinical trial drug, SGLT1/SGLT2 inhibitor or SGLT-2 inhibitor
6. Pregnant or lactating women
7. Participants in interventional clinical trials subject to other IP or medical devices within 12 weeks prior to screening
8. If the investigator is deemed unsuitable for the subject of this clinical trial due to other reasons
19 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jeil Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Severance Hospital
Seoul, Seodaemun-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JP-2266-201
Identifier Type: -
Identifier Source: org_study_id